Replies to post #2348 on Skye Bioscience Inc (SKYE)

[AntonChigurh]

http://s2.q4cdn.com/753474459/files/doc_presentations/2017/Nemus-Public-Deck_Feb-2017_FINAL.pdf

[cjarmstrong]

I meant to say they haven't tested in vivo. They wouldn't know fic without in vitro. My point was it's early and there are competitors which nobody has acknowledged that are further along, so how could I give a valuation for their MRSA potential at this stage. I don't even know what their IP is, is it just for skin infections?

[cjarmstrong]

Speaking of facts and homework, in the presentation for CINV, on page 22 they list their source for ~70% bioavailability as 'Nemus Internal Data', but I found it in a research paper Elsohly co-authored from the early 1990s. I also read an interview (pre-Nemus) where he mentioned the suppository formulation was with a pharma. I know Elsohly is extracting THC to sell to Mallinckrodt to manufacture generic dronabinol. I assume that was the company he was referring to. I wonder why that ostensibly fell through.